Related Experiment Video
Updated: Mar 5, 2026
06:41
Author Spotlight: Identification and Isolation of Quiescent Leukemia Stem Cells from Zebrafish T-ALL
Published on: July 19, 2024
1.5K
T-cell Prolymphocytic Leukemia.
1Department of Haemato-Oncology, The Royal Marsden Biomedical Research Centre, London, UK; Department of Haemato-Oncology, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, UK.
Hematology/Oncology Clinics of North America
|March 26, 2017
Summary
T-cell prolymphocytic leukemia (T-PLL) is a rare, aggressive cancer. Diagnosis integrates clinical, morphological, and molecular data, with poor outcomes despite current treatments.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive T-cell malignancy.
- Distinguishing T-PLL from other lymphoid diseases requires integrating clinical, morphological, immunophenotypic, cytogenetic, and molecular data.
Purpose of the Study:
- To summarize the diagnostic criteria and current treatment strategies for T-cell prolymphocytic leukemia.
- To highlight the need for further research into the genomic and molecular underpinnings of T-PLL to develop more effective therapies.
Main Methods:
- Review of clinical features.
- Morphological analysis.
- Immunophenotyping, cytogenetics, and molecular profiling.
Main Results:
- T-PLL is characterized by specific integrated diagnostic features.
- Current treatments include immunotherapy and stem cell transplantation, but outcomes remain poor.
Conclusions:
- Accurate diagnosis of T-PLL relies on a multi-faceted approach.
- Despite current therapeutic limitations and poor clinical outcomes, ongoing genomic and molecular research offers promise for novel treatment options for T-cell prolymphocytic leukemia.
